Clinical Trial Update: Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2 [Phase 2]

View source ↗

Summary

An ongoing Phase 2 trial evaluating the WEE1 inhibitor adavosertib (AZD1775) in advanced solid tumors with SETD2 mutations, including clear cell renal cell carc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Adavosertib (AZD1775) (adavosertib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Clear Cell Renal Cell Carcinoma, Locally Advanced Clear Cell Renal Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING